# EDGAR Filing Document

**Accession Number:** 0001849011
**File Stem:** 0001104659-23-030258
**Filing Date:** 2023-3
**Character Count:** 35193
**Document Hash:** 63496d823c6ca02f5ef038ed7dc4eec2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-030258.hdr.sgml**: 20230309

**ACCESSION NUMBER**: 0001104659-23-030258

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230308

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230309

**DATE AS OF CHANGE**: 20230309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apeiron Capital Investment Corp.
- **CENTRAL INDEX KEY:** 0001849011
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 861963522
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41030
- **FILM NUMBER:** 23718069

**BUSINESS ADDRESS:**
- **STREET 1:** 175 FEDERAL STREET
- **STREET 2:** SUITE 875
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 6179172603

**MAIL ADDRESS:**
- **STREET 1:** 175 FEDERAL STREET
- **STREET 2:** SUITE 875
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 8, 2023**

**Apeiron Capital Investment Corp.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41030** | **86-1963522** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**175 Federal Street, Suite 875**

**Boston, Massachusetts 02110**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(617) 279-0045**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| | |
|:---|:---|
| ⌧ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ◻ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ◻ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ◻ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br> Symbol(s)** | **Name of each exchange on <br> which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934 ("Exchange Act"). ◻

**Item 8.01 Other Events.**

On March 8, 2023, Apeiron Capital Investment Corp. ("**Apeiron**") and GIO World Health, Limited ("**GIO**") issued a joint press release announcing the execution of a definitive business combination agreement, dated as of March 8, 2023 (the "**Business Combination Agreement**"). Pursuant to the Business Combination Agreement, subject to the terms and conditions set forth therein, Apeiron will acquire all of the issued and outstanding shares of GIO in exchange for GIO shareholders receiving shares in Apeiron, resulting in GIO becoming a subsidiary of Apeiron. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Additional Information and Where to Find It**

In connection with the proposed transaction (the "**Proposed Transaction**"), Apeiron intends to file a registration statement on Form S-4 (as may be amended or supplemented from time to time, the "**Form S-4**" or the "**Registration Statement**") with the U.S. Securities and Exchange Commission (the "**SEC**"), which will include a preliminary proxy statement and a prospectus in connection with the Proposed Transaction. STOCKHOLDERS OF APEIRON ARE ADVISED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT, ANY AMENDMENTS THERETO, THE DEFINITIVE PROXY STATEMENT, THE PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. HOWEVER, THIS DOCUMENT WILL NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION. IT IS ALSO NOT INTENDED TO FORM THE BASIS OF ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF THE PROPOSED TRANSACTION. When available, the definitive proxy statement and other relevant documents will be mailed to the stockholders of Apeiron as of a record date to be established for voting on the Proposed Transaction. Stockholders and other interested persons will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, the Registration Statement and other documents filed by Apeiron with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's website at http://www.sec.gov.

Apeiron's stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to: 175 Federal Street, Suite 875, Boston, MA 02110; email: apeiron@ershares.com. These documents, once available, can also be obtained, without charge, at the SEC's website www.sec.gov.

**Participants in the Solicitation**

Apeiron, GIO and their respective directors and executive officers may be deemed participants in the solicitation of proxies of Apeiron's stockholders in connection with the Proposed Transaction. Apeiron's stockholders and other interested persons may obtain more detailed information regarding the names, affiliations, and interests of certain of Apeiron executive officers and directors in the solicitation by reading Apeiron's final prospectus filed with the SEC on November 10, 2021 in connection with Apeiron's initial public offering ("**IPO**"), Apeiron's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 22, 2022 and Apeiron's other filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the Proposed Transaction, which may, in some cases, be different from those of stockholders generally, will be set forth in the Registration Statement relating to the Proposed Transaction when it becomes available. These documents can be obtained free of charge from the source indicated above.

**No Offer or Solicitation**

This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "**Securities Act**") or an exemption therefrom.

**Forward-Looking Statements**

This report contains forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding GIO and the Proposed Transaction and the future held by the respective management teams of Apeiron or GIO, the anticipated benefits and the anticipated timing of the Proposed Transaction, future financial condition and performance of GIO and expected financial impacts of the Proposed Transaction (including future revenue, pro forma enterprise value and cash balance), the satisfaction of closing conditions to the Proposed Transaction, financing transactions, if any, related to the Proposed Transaction, the level of redemptions of Apeiron's public stockholders and the products and markets and expected future performance and market opportunities of GIO These forward-looking statements generally are identified by the words "anticipate," "believe," "could," "expect," "estimate," "future," "intend," "may," "might," "strategy," "opportunity," "plan," "project," "possible," "potential," "project," "predict," "scales," "representative of," "valuation," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including, without limitation: (i) the risk that the Proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Apeiron's securities, (ii) the risk that the Proposed Transaction may not be completed by Apeiron's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Apeiron, (iii) the failure to satisfy the conditions to the consummation of the Proposed Transaction, including, among others, the requirement that the definitive agreement related to the business combination between Apeiron and GIO (the "**Business Combination Agreement**") and the transactions contemplated thereby be approved by the stockholders of Apeiron and by the stockholders of GIO, respectively, (iv) the failure to obtain regulatory approvals, as applicable, required to consummate the Proposed Transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement, (vi) the effect of the announcement or pendency of the Proposed Transaction on GIO's business relationships, operating results, and business generally, (vii) risks that the Proposed Transaction disrupts current plans and operations of GIO, (viii) the outcome of any legal proceedings that may be instituted against GIO or against Apeiron related to the Business Combination Agreement or the Proposed Transaction, (ix) the ability of Apeiron's securities to once again become listed on a national securities exchange, (x) changes in the competitive market in which GIO operates, variations in performance across competitors, changes in laws and regulations affecting GIO's business and changes in the combined capital structure, (xi) the ability to implement business plans, growth, marketplace and other expectations after the completion of the Proposed Transaction, and identify and realize additional opportunities, (xiii) the potential inability of GIO to achieve its business and customer growth, and (xiv) the ability of GIO to enforce its current or future intellectual property, along with potential claims of infringement by GIO of the intellectual property rights of others. The foregoing list of factors is not exhaustive. Recipients should carefully consider such factors and the other risks and uncertainties described and to be described in the "Risk Factors" section of Apeiron's initial public offering prospectus filed with the SEC on November 10, 2021, Apeiron's Annual Report on Form 10-K filed for the year ended December 31, 2021, as filed with the SEC on March 22, 2022 and subsequent periodic reports filed by Apeiron with the SEC, the Registration Statement to be filed by Apeiron in connection with the Proposed Transaction and other documents filed or to be filed by Apeiron from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Recipients are cautioned not to put undue reliance on forward-looking statements, and neither GIO nor Apeiron assume any obligation to, nor intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Neither GIO nor Apeiron gives any assurance that either GIO or Apeiron, or the combined company, will achieve its expectations.

**Information Sources; No Representations**

The communication furnished herewith has been prepared for use by Apeiron and GIO in connection with the transaction. The information therein does not purport to be all-inclusive. The information therein is derived from various internal and external sources, with all information relating to the business, past performance, results of operations and financial condition of Apeiron derived entirely from Apeiron and all information relating to the business, past performance, results of operations and financial condition of GIO derived entirely from GIO No representation is made as to the reasonableness of the assumptions made with respect to the information therein, or to the accuracy or completeness of any projections or modeling or any other information contained therein. Any data on past performance or modeling contained therein is not an indication as to future performance.

No representations or warranties, express or implied, are given in respect of the communication. To the fullest extent permitted by law in no circumstances will Apeiron or GIO, or any of their respective subsidiaries, affiliates, shareholders, representatives, partners, directors, officers, employees, advisors or agents, be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of the this communication (including without limitation any projections or models), any omissions, reliance on information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith, which information relating in any way to the operations of GIO has been derived, directly or indirectly, exclusively from GIO and has not been independently verified by Apeiron. Neither the independent auditors of Apeiron nor the independent auditors of or GIO audited, reviewed, compiled or performed any procedures with respect to any projections or models for the purpose of their inclusion in the communication and, accordingly, neither of them expressed any opinion or provided any other form of assurances with respect thereto for the purposes of the communication.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm238984d1_ex99-1.htm) | [Press release, dated March 8, 2023](tm238984d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Apeiron Capital Investment Corp.** | **Apeiron Capital Investment Corp.** |
| By: | /s/ Joel Shulman |
|  | Name: Joel Shulman |
|  | Title: Chief Executive Officer |

---

Dated: March 8, 2023

## Exhibit 99.1

**Exhibit 99.1**

![](logo.jpg)

**GIO World Health Ltd, a Leading Stem Cell Life Science Company, Announces Plans to Go Public via Business Combination with Apeiron Capital Investment Corp.**

&nbsp;&nbsp;&nbsp;&nbsp;· **GIO World Health Ltd ("GIO World Health") has entered into a business combination agreement with Apeiron Capital Investment Corp (APNC).** 

&nbsp;&nbsp;&nbsp;&nbsp;· **The post-closing combined public company, which will be named GIO World Health Holdings, Inc., values GIO World Health in the proposed transaction at a pre-money enterprise value of $250 million.** 

&nbsp;&nbsp;&nbsp;&nbsp;· **Current GIO World Health shareholders will retain 100% of their equity in the post-closing combined public company and will continue to own approximately 80.83% of the post-closing combined public company on a pro forma basis, assuming no redemptions by Apeiron Capital's public shareholders, and that all GIO World Health shareholders participate in the transaction.** 

BOSTON, MA and SAN DIEGO, CA – March 8, 2023 / (Globe Newswire)— GIO World Health, a recently formed company focused on stem cell research and development, and Apeiron Capital Investment Corp. ("Apeiron Capital") (OTC: APNC), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the "BCA") to bring GIO World Health public in order to bring its proprietary stem cell treatments to market, and other stem cell based products for global consumption. The parties intend that at the closing of the proposed transaction (the "Closing"), Apeiron Capital common stock will be listed on either the New York Stock Exchange or NASDAQ, and Apeiron Capital will be renamed "GIO World Health Holdings, Inc.".

GIO World Health, was founded in 2021 by Dr. Anand Srivastava and Deven Patel, accomplished professionals who have operated in the stem cell research and development field for over two decades. Beginning in the late 1990's, Dr. Anand Srivastava has been pursuing pioneering stem cell research and potential applications at some of the leading academic universities around the world. He has published extensively in top academic journals and has received numerous awards recognizing him for his contributions to the sciences.

GIO World Health is a stem cell-based life science company with plans to distribute selective products and services globally, and may also pursue FDA approval for more advanced therapies. GIO World Health is planning to mass produce the Red Blood Cells (RBCs) from stem cells in a bioreactor to solve the blood shortage problem. Furthermore, they also plan to provide proprietary stem cell-based therapies through their Longevity ("Anti-Aging") clinics, which are expected to commence in the second half of 2023 with continuing expansion efforts in subsequent years. The clinics will focus initially on targeted non-U.S. locations and utilize the role of stem cells in anti-aging treatments. GIO World Health senior management have an extensive track record of having provided anti-aging treatments to patients outside of the U.S. Expansion to non-U.S. locations is intended to utilize local partners to help expedite corporate growth. Another stream of revenue is expected from GIO World Health's "Active Cosmetics" line of products that leverage their stem cell technology. GIO World Health will offer a range of skin care products that will help improve vascularization to skin and healing of inflammation-injured cells. Their products will focus initially on the "Active Cosmetics" category including: anti-wrinkle, facial serum, daytime skin cream, under eye anti-wrinkle serum, high-end cream and hair vitality formulation. GIO World Health intends to seek strategic partnerships to help streamline product branding and distribution. GIO World Health also currently expects to have a revenue stream in the future to be derived from the development of a cost-effective disease-free universal donor (O negative) alternative to donor blood.

The GIO World Health organization will continue to be led under its highly experienced leadership of Dr. Anand Srivastava, Ph.D. and Mr. Deven Patel, who will become executive officers of the post-Closing public company at the Closing.

**Management Comments**

Deven Patel, Chief Executive Officer of GIO World Health said: "We are delighted to partner with Apeiron Capital in this business combination, a significant milestone toward creating value for our shareholders. This business combination and entry into the public markets will allow us access to a much larger pool of capital and increase our global profile for several clinical trials. We believe that this Transaction will put us in a position to quickly grow in what we see as a $100+ billion industry in the U.S. and global market that is projected to grow at a 10+% CAGR."<sup>1</sup>

Joel Shulman, Chief Executive Officer of Apeiron Capital said: "We are very pleased to support GIO World Health in its transition to the public markets where our combined contributions have the ability to accelerate value for our shareholders. GIO World Health founders impressed us with their proprietary research and practical solutions in high growth markets. This opportunity provides a series of potential revenue streams including Longevity Clinics and Active Cosmetics that should start to provide accretive revenues in the first year. Furthermore, its management has proprietary expertise in developing a cost-effective disease-free, universal donor (O negative) alternative to donor blood that can potentially help revolutionize the manner in which clean blood is produced in the lab and distributed throughout the world. GIO World Health's management has an extensive history of proprietary research and practical solutions. We believe that GIO World Health is well-positioned to capture the many opportunities in the HealthCare industry, and we look forward to seeing the company grow and thrive in the public markets."

<sup>1</sup> Sources:

&nbsp;&nbsp;&nbsp;&nbsp;· https://www.globenewswire.com/news-release/2022/12/08/2570057/0/en/The-global-active-cosmetics-market-is-expected-to-grow-at-a-CAGR-of-12-64-during-2021-2027.html

&nbsp;&nbsp;&nbsp;&nbsp;· https://www.arizton.com/market-reports/active-cosmetics-market

&nbsp;&nbsp;&nbsp;&nbsp;· https://www.grandviewresearch.com/industry-analysis/plasma-fractionation-market-report

· https://www.precedenceresearch.com/stem-cell-therapy-market#:~:text=The%20global%20stem%20cell%20therapy,forecast%20period%202022%20to%202030

**Transaction Overview**

Under the BCA, Apeiron Capital will acquire shares of GIO World Health from its existing shareholders in exchange for newly issued common shares of Apeiron Capital (the "**Transaction**"). GIO shareholders holding approximately 98.7% of its outstanding shares have signed on to sell their shares to Apeiron Capital under the BCA, and the parties intend to have the remaining GIO shareholders participate in the Transaction prior to the Closing. Under the terms of the BCA, GIO World Health is valued at a pre-money enterprise value of $250 million.

Upon the Closing, current GIO World Health shareholders will retain 100% of their equity through new common shares of Apeiron Capital and own approximately 80.83% of the post-closing combined public company at the Closing, in each case assuming no redemptions by Apeiron Capital's public shareholders. and that all GIO World Health shareholders participate in the Transaction.

The Transaction is expected to close in the second half of 2023 and is subject to approval by Apeiron Capital's shareholders and other customary closing conditions.

**Advisors**

TAG Partners Ltd. is serving as the capital markets and financial advisor to GIO World Health. Ellenoff Grossman & Schole LLP is serving as legal advisor to Apeiron Capital, and Winston & Strawn LLP is serving as legal advisor to GIO World Health.

**About GIO World Health**

GIO World Health is a life sciences company that engages in the business of stem cell-based technologies, and plans to provide products and services throughout the world. Its mission is to make the world a healthier place by providing stem cell therapy and leveraging stem cell science and technology.

**About Apeiron Capital**

Apeiron Capital is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. While Apeiron Capital may pursue an acquisition opportunity in any industry or sector, it focused its search on companies in the financial technology, Healthcare and Health Science sectors. Apeiron Capital is led by Chief Executive Officer Joel Shulman, Chief Operating Officer Eva Adosoglou and Chief Financial Officer Grant Grigorian. Apeiron Capital's independent directors include Jeffrey Mortimer, Kevin Cramton, and Charles Aggouras.

**Forward-Looking Statements**

This press release includes "forward-looking statements" within the meaning of within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Statements regarding Apeiron Capital and GIO World Health's expectations with respect to anticipated financial impacts of the proposed Transaction, the timing of the completion of the proposed Transaction, GIO World Health's projected financial and operational performance, new product offerings that GIO World Health may introduce, and related matters, as well as all other statements other than statements of historical fact included in this press release, are forward-looking statements. When used in this press release, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions, as they relate to Apeiron Capital or GIO World Health's management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, Apeiron Capital's and GIO World Health's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in Apeiron Capital's filings with the Securities and Exchange Commission ("SEC"). Most of these factors are outside the control of Apeiron Capital and are difficult to predict. In addition to factors disclosed in Apeiron Capital filings with the SEC, the following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: the risk that the Transaction may not be completed in a timely manner or at all, which may adversely affect the price of the securities of Apeiron Capital; the risk that the Transaction may not be completed by Apeiron Capital's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Apeiron Capital; inability to meet the closing conditions to the Transaction, including the occurrence of any event, change, legal proceedings instituted against GIO World Health or against Apeiron Capital related to the BCA or the management team, or other circumstances that could give rise to the termination of the BCA; the inability to complete the Transaction contemplated by the BCA due to the failure to obtain approval of Apeiron Capital's shareholders; the failure to list Apeiron Capital's common shares or other securities on a national stock exchange in connection with the consummation of the contemplated Transaction; costs related to the Transaction and the failure to realize anticipated benefits of the Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated shareholder redemptions; a delay or failure to realize the expected benefits from the proposed Transaction including GIO World Health's ability to effectively develop and successfully market new products, solutions and services, and to effectively address cost reductions and other changes in its industry; risks related to disruption of management's time from ongoing business operations due to the proposed Transaction; changes in the markets in which GIO World Health competes, including with respect to its competitive landscape, technology evolution or the impact of regulatory changes on solutions, services, labor matters, international economic, political, legal, compliance and business factors; developments and uncertainties in domestic and foreign trade policies and regulations, and other regulations which may cause contractions or affect growth rates and cyclicality of markets GIO World Health serves; disruptions relating to war, terrorism, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events; changes in domestic and global general economic conditions; risk that GIO World Health may not be able to execute its growth strategies; security breaches or other disruptions of GIO World Health information technology systems or violations of data privacy laws; risks related to the ongoing COVID-19 pandemic and response, including new variants of the virus; the pace of recovery in the markets in which GIO World Health operates; global supply chain disruptions and potential staffing shortages at potential customers which may have a trickle- down effect on GIO World Health; the risk that GIO World Health may not be able to develop and maintain effective internal controls; changes in interest rates; increased competition and the ability to generate sufficient cash to fulfill obligations; loss of certain key officers; loss of continued relationships with customers or bus operators; and Apeiron Capital's success at managing the foregoing items. The forward-looking statements are based upon management's beliefs and assumptions; and other risks and uncertainties to be identified in the Form S-4 registration/proxy statement (when available) relating to the Transaction, including those under "Risk Factors" therein, and in other filings with the SEC made by Apeiron Capital. Each of Apeiron Capital and GIO World Health undertake no obligation to update these statements for revisions or changes after the date of this press release except as required by law.

**Additional Information and Where to Find It**

In connection with the proposed Transaction, Apeiron intends to file a Registration Statement on Form S-4 (the "Registration Statement") with the SEC, which will include a preliminary prospectus with respect to its securities to be issued in connection with the Transaction and a preliminary proxy statement with respect to Apeiron Capital's shareholder meeting at which Apeiron Capital's shareholders will be asked to vote on the proposed Transaction. Each of Apeiron Capital and GIO World Health urge investors, shareholders, and other interested persons to read, when available, the Registration Statement, including the proxy statement/prospectus, any amendments thereto, and any other documents filed with the SEC, before making any voting or investment decision because these documents will contain important information about the proposed Transaction. After the Registration Statement has been filed and declared effective, Apeiron Capital will mail the definitive proxy statement/prospectus to shareholders of Apeiron Capital as of a record date to be established for voting on the Transaction. Apeiron Capital's shareholders will also be able to obtain a copy of such documents, without charge, by directing a request to: Apeiron Capital Acquisition Corp, 175 Federal Street, Suite 875 Boston, Massachusetts 02110; e-mail: Apeiron Capital@ershares.com. These documents, once available, can also be obtained, without charge, at the SEC's website www.sec.gov.

**Participants in the Solicitation**

Apeiron Capital and its directors and officers may be deemed participants in the solicitation of proxies of Apeiron Capital's shareholders in connection with the proposed Transaction. Security holders may obtain more detailed information regarding the names, affiliations, and interests of certain of Apeiron Capital's executive officers and directors in the solicitation by reading Apeiron Capital's final prospectus filed with the SEC on November 10, 2021, and the Registration Statement and other relevant materials filed with the SEC in connection with the Transaction when they become available. Information concerning the interests of Apeiron Capital's participants in the solicitation, which may, in some cases, be different from those of their shareholders generally, will be set forth in the Registration Statement relating to the Transaction when it becomes available. These documents can be obtained free of charge from the source indicated above.

GIO World Health and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Apeiron Capital in connection with the proposed Transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed Transaction will be included in the Registration Statement for the proposed Transaction.

**No Offer or Solicitation**

This press release does not constitute an offer to sell or a solicitation of an offer to buy, or the solicitation of any vote or approval in any jurisdiction in connection with the proposed Transaction or any related transactions, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful. Any offering of securities or solicitation of votes regarding the proposed transaction will be made only by means of a proxy statement/prospectus that complies with applicable rules and regulations promulgated under the Securities Act of 1933, as amended (the "Securities Act"), and Securities Exchange Act of 1934, as amended, or pursuant to an exemption from the Securities Act or in a transaction not subject to the registration requirements of the Securities Act.

**Contact Information**

Joel Shulman

Chief Executive Officer

Apeiron Capital Acquisition Corp

Email: info@apeironac.com

Phone: (617) 279-0045

Website: www.apeironac.com

Deven Patel

Chief Executive Officer

GIO World Health, Limited

Email: info@gioworldhealth.com

Phone: (800) 914-7836

Website: www.gioworldhealth.com